175 related articles for article (PubMed ID: 15209771)
1. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles.
Rave K; Nosek L; Heinemann L; Gonzales C; Ernest CS; Chien J; Muchmore D
Diabet Med; 2004 Jul; 21(7):763-8. PubMed ID: 15209771
[TBL] [Abstract][Full Text] [Related]
2. PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler.
Heise T; Brugger A; Cook C; Eckers U; Hutchcraft A; Nosek L; Rave K; Troeger J; Valaitis P; White S; Heinemann L
Diabetes Obes Metab; 2009 May; 11(5):455-9. PubMed ID: 19236443
[TBL] [Abstract][Full Text] [Related]
3. Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
Steiner S; Pfützner A; Wilson BR; Harzer O; Heinemann L; Rave K
Exp Clin Endocrinol Diabetes; 2002 Jan; 110(1):17-21. PubMed ID: 11835120
[TBL] [Abstract][Full Text] [Related]
4. Time-action profile of inhaled insulin.
Heinemann L; Traut T; Heise T
Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
[TBL] [Abstract][Full Text] [Related]
5. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB
Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
[TBL] [Abstract][Full Text] [Related]
8. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
Cernea S; Kidron M; Wohlgelernter J; Raz I
Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.
Rave K; Potocka E; Heinemann L; Heise T; Boss AH; Marino M; Costello D; Chen R
Diabetes Obes Metab; 2009 Jul; 11(7):715-20. PubMed ID: 19476477
[TBL] [Abstract][Full Text] [Related]
10. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system.
Wise S; Chien J; Yeo K; Richardson C
Diabet Med; 2006 May; 23(5):510-5. PubMed ID: 16681559
[TBL] [Abstract][Full Text] [Related]
11. Inhaled insulin--does it become reality?
Siekmeier R; Scheuch G
J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():81-113. PubMed ID: 19218634
[TBL] [Abstract][Full Text] [Related]
12. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics.
de la Peña A; Seger M; Rave K; Heinemann L; Silverman B; Muchmore DB
Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S75-80. PubMed ID: 19772452
[TBL] [Abstract][Full Text] [Related]
13. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes.
Kim D; Mudaliar S; Chinnapongse S; Chu N; Boies SM; Davis T; Perera AD; Fishman RS; Shapiro DA; Henry R
Diabetes Care; 2003 Oct; 26(10):2842-7. PubMed ID: 14514589
[TBL] [Abstract][Full Text] [Related]
14. AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma.
Wolzt M; de la Peña A; Berclaz PY; Tibaldi FS; Gates JR; Muchmore DB
Diabetes Care; 2008 Apr; 31(4):735-40. PubMed ID: 18192544
[TBL] [Abstract][Full Text] [Related]
15. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
16. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.
Rave KM; Nosek L; de la Peña A; Seger M; Ernest CS; Heinemann L; Batycky RP; Muchmore DB
Diabetes Care; 2005 Oct; 28(10):2400-5. PubMed ID: 16186270
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients.
Brunner GA; Balent B; Ellmerer M; Schaupp L; Siebenhofer A; Jendle JH; Okikawa J; Pieber TR
Diabetologia; 2001 Mar; 44(3):305-8. PubMed ID: 11317660
[TBL] [Abstract][Full Text] [Related]
18. Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term.
Prescrire Int; 2006 Dec; 15(86):203-9. PubMed ID: 17165235
[TBL] [Abstract][Full Text] [Related]
19. Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
Kapitza C; Heise T; Fishman RS; Shapiro DA; Gopalakrishnan V; Rave K; Bott S; Perera AD; Heinemann L
Diabetes Technol Ther; 2004 Apr; 6(2):119-27. PubMed ID: 15117578
[TBL] [Abstract][Full Text] [Related]
20. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
